Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Frontiers in Pharmacology
|
August 19, 2022
Fucoxanthin: A Promising Phytochemical on Diverse Pharmacological Targets
Mumtaza Mumu, Ayan Das, Talha Bin Emran, et al.
The Journal of Clinical Investigation
|
March 14, 2024
Adult and neonatal models of chemogenetic heart failure caused by oxidative stress
Fotios Spyropoulos, Apabrita Ayan Das, Markus Waldeck-Weiermair, et al.
Virulence
|
April 1, 2022
Pathogenicity and virulence of Marburg virus
Mehedy Hasan Abir, Tanjilur Rahman, Ayan Das, et al.
CNS Drugs
|
March 2, 2022
Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
Huixin Yu, Gordon Graham, Olivier J David, et al.
Neurology and Therapy
|
July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Stephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Neurology and Therapy
|
May 3, 2022
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
Anne H Cross, Silvia Delgado, Mario Habek, et al.
Neurology and Therapy
|
March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
Anne H Cross, Silvia Delgado, Mario Habek, et al.
Dementia and Geriatric Cognitive Disorders Extra
|
October 2, 2019
Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
Kengo Ueda, Sadao Katayama, Tetsuaki Arai, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 1, 2022
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Stephen L Hauser, Anne H Cross, Kevin Winthrop, et al.
Omics : a Journal of Integrative Biology
|
December 21, 2018
Proteomic Analysis of the Human Anterior Pituitary Gland
Soujanya D Yelamanchi, Ankur Tyagi, Varshasnata Mohanty, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Frontiers in Pharmacology
|
August 19, 2022
Fucoxanthin: A Promising Phytochemical on Diverse Pharmacological Targets
Mumtaza Mumu, Ayan Das, Talha Bin Emran, et al.
The Journal of Clinical Investigation
|
March 14, 2024
Adult and neonatal models of chemogenetic heart failure caused by oxidative stress
Fotios Spyropoulos, Apabrita Ayan Das, Markus Waldeck-Weiermair, et al.
Virulence
|
April 1, 2022
Pathogenicity and virulence of Marburg virus
Mehedy Hasan Abir, Tanjilur Rahman, Ayan Das, et al.
CNS Drugs
|
March 2, 2022
Population Pharmacokinetic-B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis
Huixin Yu, Gordon Graham, Olivier J David, et al.
Neurology and Therapy
|
July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment
Stephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Neurology and Therapy
|
May 3, 2022
Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
Anne H Cross, Silvia Delgado, Mario Habek, et al.
Neurology and Therapy
|
March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
Anne H Cross, Silvia Delgado, Mario Habek, et al.
Dementia and Geriatric Cognitive Disorders Extra
|
October 2, 2019
Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
Kengo Ueda, Sadao Katayama, Tetsuaki Arai, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
March 1, 2022
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Stephen L Hauser, Anne H Cross, Kevin Winthrop, et al.
Omics : a Journal of Integrative Biology
|
December 21, 2018
Proteomic Analysis of the Human Anterior Pituitary Gland
Soujanya D Yelamanchi, Ankur Tyagi, Varshasnata Mohanty, et al.
Page
of 9